1. Home
  2. MAS vs ABVX Comparison

MAS vs ABVX Comparison

Compare MAS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Masco Corporation

MAS

Masco Corporation

N/A

Current Price

$70.66

Market Cap

14.4B

Sector

Industrials

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$113.57

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAS
ABVX
Founded
1929
2013
Country
United States
France
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
11.9B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
MAS
ABVX
Price
$70.66
$113.57
Analyst Decision
Buy
Buy
Analyst Count
15
13
Target Price
$80.13
$131.31
AVG Volume (30 Days)
1.5M
790.5K
Earning Date
04-22-2026
03-23-2026
Dividend Yield
1.80%
N/A
EPS Growth
2.66
N/A
EPS
1.05
N/A
Revenue
$7,562,000,000.00
N/A
Revenue This Year
$2.70
$52.14
Revenue Next Year
$3.40
$4,132.27
P/E Ratio
$66.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$58.16
$69.81
52 Week High
$83.64
$148.83

Technical Indicators

Market Signals
Indicator
MAS
ABVX
Relative Strength Index (RSI) 37.64 41.95
Support Level $68.42 $107.67
Resistance Level $71.56 $129.00
Average True Range (ATR) 1.39 3.40
MACD -0.30 -0.54
Stochastic Oscillator 7.12 35.45

Price Performance

Historical Comparison
MAS
ABVX

About MAS Masco Corporation

Masco is a global manufacturer of branded home improvement products, with a focus on plumbing fixtures (70% of revenue) and decorative architectural coatings (30% of revenue). The company primarily serves the repair and remodel market, with products such as faucets, showerheads, and paint sold through retail, wholesale, and e-commerce channels. Its portfolio includes well-known brands such as Delta, Hansgrohe, and Behr.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: